ATS Corporation (ATS) Q4 2026 earnings review
Restructuring the Future: Weak Bookings Overshadow Deleveraging Success
ATS ends FY26 amid a massive operational pivot. Do not be fooled by the reported 30.1% YoY revenue growth—this is entirely a statistical mirage created by last year's $146.9M EV customer settlement write-down. Adjusted organic revenue grew an anemic 1.5%. More concerning is the 18.4% collapse in order bookings, which drained the backlog by 8.5% to $1.96B and pushed the trailing book-to-bill ratio slightly below 1.0x (0.99:1). Management is aggressively cutting its losses in the Transportation sector, absorbing heavy restructuring charges to pivot toward higher-margin Energy and Life Sciences projects. The brightest spot is capital discipline: ATS generated a massive $124.1M in Q4 Free Cash Flow, successfully driving leverage down to 2.8x, back within management's target range.
🐂 Bull Case
Net Debt to Adjusted EBITDA improved to 2.8x, down from 3.9x a year ago. Non-cash working capital dropped to 12.1% of adjusted revenues, beating the <15% target. This restored balance sheet flexibility paves the way for a return to strategic M&A.
Energy adjusted revenue doubled (+101.5%) on the back of long-cycle nuclear projects, while Consumer Products jumped 80.6%, driven by large warehouse packaging automation deployments.
🐻 Bear Case
Order bookings plummeted 18.4% YoY, dragging total backlog down 8.5% to $1,958M. The vital Life Sciences segment saw bookings decline, signaling potential hesitation in customer capital deployment.
Life Sciences, ATS's largest and historically most reliable profit engine, posted a 9.3% YoY decline in adjusted revenue ($378.0M vs $416.9M), failing to offset the planned collapse in Transportation.
⚖️ Verdict: ⚪
Neutral. The cleanup of the balance sheet and decisive exit from dilutive Transportation contracts are net positives. However, the steep drop in bookings and contraction in the core Life Sciences segment raise immediate concerns about top-line growth for FY27.
Key Themes
Order Bookings Collapse
Q4 Order Bookings fell sharply by 18.4% YoY to $704M, reflecting a 19.3% decline in organic bookings. Decreases were observed across Life Sciences, Consumer Products, and Energy. Management attributes this to 'timing of customer capital investment cycles,' but this broad-based hesitation pushed the TTM book-to-bill ratio to 0.99:1, signaling that the company is currently burning through its backlog faster than it can replenish it.
Energy Segment's Nuclear Renaissance
Energy was the standout performer, with adjusted revenue jumping 101.5% YoY to $67.9M. The execution of high-value nuclear reactor refurbishments and early participation in new reactor builds (including Small Modular Reactors) are transforming this segment into a highly reliable, long-cycle growth engine for ATS.
Transportation Restructuring Bloodbath
The long-awaited exit from low-margin EV and Transportation contracts is proving costly. Q4 included a $28.3M hit for transportation reorganization (aged inventory adjustments, impairment charges, and legacy contract completion costs). Transportation adjusted revenue collapsed 61.1% YoY to just $26.6M. Management intends to stop reporting Transportation as a separate vertical entirely in coming quarters.
Life Sciences Growth Sputters
Despite a strong overarching narrative around radiopharmaceuticals and auto-injectors (GLP-1), Life Sciences adjusted revenues fell 9.3% YoY in Q4. Management pointed to a lower opening backlog compared to the prior year, which had benefited from several large enterprise bookings. If this 'lumpiness' turns into a structural slowdown in lab capital expenditure, ATS's primary margin engine will be at risk.
Working Capital Efficiency Restored
A massive operational win: non-cash working capital as a percentage of annualized adjusted revenues plummeted to 12.1%, easily beating management's long-term goal of remaining below 15%. This drove $149.5M in Q4 operating cash flow and gives ATS immense flexibility heading into FY27.
Services Reorganization for Margin Expansion
ATS booked a $9.8M charge in Q4 to restructure its services organization, intentionally embedding these capabilities directly into the operating units. This is a targeted commercial practice designed to increase aftermarket mix, capture recurring revenue, and drive the guided 50-75 bps margin improvement in FY27.
Tariff and Supply Chain Exposure
Macro uncertainty persists around shifting global trade dynamics. Just over 20% of ATS's trailing twelve-month equipment and product adjusted revenues involved shipments from Canadian and European operations into the U.S. While management states current U.S. Section 232 tariffs have no material impact and supply chains are mitigated via alternative sourcing, any breakdown in USMCA agreements poses a tangible tail-risk to cross-border margins.
Expanding Capabilities in Automation Tech
The company continues to lean heavily into high-tech automation niches to differentiate itself. Current funnel strength relies on radiopharmaceutical applications, automated pharmacy solutions, medical wearables, and grid battery storage. By repositioning leftover engineering talent from the defunct Transportation unit into machine vision and high-precision laser welding for these newer segments, ATS is upgrading its overall technological margin profile.
Other KPIs
Accelerating. Up massively from just $10.3M in the prior-year period. Full-year FY26 FCF hit $371.7M compared to negative $(52.3)M in FY25. This was the primary engine that allowed ATS to de-lever its balance sheet ahead of schedule.
Accelerating/Improving. Down significantly from 3.9x in Q4 of last year, and 3.6x in Q1 of this year. ATS has successfully returned to its target leverage range of 2.0x to 3.0x, effectively removing the debt-handcuffs that paused large M&A activity in prior quarters.
Stable. Up slightly by 31 basis points YoY (from 13.5%). Full-year FY26 Adjusted EBITDA margin was 13.9%. The incremental improvement shows that shedding the dilutive EV business is beginning to yield the promised profitability mix shift.
Guidance
Decelerating. The midpoint of $720M represents a sequential step down from Q4's adjusted revenue of $744.3M, and falls notably short of the $736.7M delivered in Q1 2026. This soft guide aligns with the sharp 18% drop in recent order bookings.
Accelerating. Management explicitly expects margin expansion driven by the removal of ~$50M in dilutive transportation revenues, disciplined ABM execution, and an improved aftermarket mix from the services reorganization. This remains a bridge toward their unchanged long-term target of 15%.
Decelerating. Compared to FY26's adjusted revenue growth of 10.8%, 'modest growth' signals a significant top-line slowdown. The backlog normalization in Life Sciences and the intentional shrinking of Transportation are acting as near-term growth anchors.
Key Questions
Bookings Normalization vs Structural Slowdown
Order bookings declined 18% this quarter, bringing the TTM book-to-bill slightly below 1.0x. How much of this is truly due to tough comps from last year's 'enterprise orders' versus a genuine delay in customer capital deployments in the current macro environment?
Life Sciences Trajectory
Life Sciences adjusted revenue declined 9% YoY. With government lab funding facing pressure and GLP-1 capacity catching up, when do you expect Life Sciences revenue growth to re-accelerate?
Capital Deployment Priorities
Now that you have successfully reduced Net Debt to Adjusted EBITDA to 2.8x (back in the target zone), how does the prioritization rank between resuming large-scale M&A, increasing internal R&D, or aggressively utilizing the NCIB share buyback program?
Transportation Exit Strategy
You are marketing two US facilities and one in Germany for sale as part of the Transportation segment wind-down. Are there any remaining legacy contracts that could trigger further negative gross margin adjustments in FY27 before the exit is complete?